



iSonea Achieves Therapeutic Goods Administration (TGA) Listing for AirSonea™

Regulatory clearance achieves final key milestone for September 2013 launch in Australia

Melbourne, Australia and Severna Park, MD, USA – 6 August 2013 – Medical technology company iSonea Limited (ASX: ISN) has received approval from Australian regulatory authorities to list its innovative product, the AirSonea wheeze detection and monitoring device.

This listing on the Australian Register of Therapeutic Goods (ARTG) is a critical Company milestone as it prepares to launch the device - which will enable wheeze rate monitoring via smartphones and a cloud based analytical system - for the first time in Australia next month.

iSonea Chief Executive Office Michael Thomas said this TGA listing provided further validation of the Company's technology, as well as the Acoustic Respiratory Monitoring (ARM™) platform underpinning all iSonea products.

"Inclusion on the TGA register is an important step for our Company as we complete the final stages of commercial launch preparation," he said.

"We look forward to bringing this important technology to market in September that will change the way millions of asthmatics around the world can manage and monitor their breathing symptoms."

Ends.

Media Inquiries:

Mr Michael Thomas
Chief Executive Officer
iSonea Limited
+1 410-777-5251
mthomas@iSoneaMed.com

Emma Power
Monsoon Communications
+61 (0) 419 149 525
emmap@monsoon.com.au

Dr Stewart Washer
Chairman
+61 (0) 418 288 212
swasher@isoneamed.com

Websites: www.iSoneaMed.com, www.SoundAsthma.com

About iSonea Limited

iSonea Limited (ASX:ISN) is an emerging medical technology company developing innovative, non-invasive devices and mobile health apps to improve the management of chronic, costly respiratory disorders such as asthma and COPD. By leveraging iSonea's proprietary Acoustic Respiratory Monitoring™ (ARM) technology with its AsthmaSense™ mobile applications, iSonea is turning smart phones into medical devices--enabling anyone, anywhere, at any time to monitor breathing distress symptoms, in order to take action. iSonea's ARM devices have been cleared for use by the U.S. Food and Drug Administration, the Australian TGA and the European Union CE.

For more information, please visit www.iSoneaMed.com and www.SoundAsthma.com

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on iSonea's current expectations, estimates and projections about the industry in which iSonea operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of iSonea, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. iSonea cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of iSonea only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. iSonea will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.